UK CMA disqualifies pharma company director after breaking competition law
A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
List view / Grid view
A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
The CMA has announced Tiofarma admits taking part in an anti-competitive agreement with Amilco and Aspen which resulted in huge price increase in fludrocortisone acetate tablets.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.